CHMP Recommends T-DXd Plus Pertuzumab for First-Line HER2-Positive Metastatic Breast Cancer

EU regulatory committee (CHMP) recommended approval of T-DXd plus pertuzumab as first-line treatment for HER2-positive metastatic breast cancer, based on DESTINY-Breast09 trial data showing 44% reduction in disease progression or death versus current standard of care. FDA approved the same combination in December 2025.

This Wire brief sits within Fusion42's coverage of Digital Health. Wire is Fusion42's founder-focused intelligence feed: each story is connected to the funds and startups it names — every one with a live profile on Raise or Scout — so founders can follow the capital and the momentum behind the headline rather than just the headline itself. Wire analysis is one of the live surfaces Arthur reasons over.